| 1 |
35595082 | SARS-CoV-2 Permissive glioblastoma cell line for high throughput antiviral screening. | 2022 Jul |
1 |
| 2 |
32375574 | Repurposing of chloroquine and some clinically approved antiviral drugs as effective therapeutics to prevent cellular entry and replication of coronavirus. | 2021 Jul |
1 |
| 3 |
33179852 | Human soluble ACE2 improves the effect of remdesivir in SARS-CoV-2 infection. | 2021 Jan 11 |
1 |
| 4 |
34229582 | The molecular dynamics of possible inhibitors for SARS-CoV-2. | 2021 Jul 6 |
1 |
| 5 |
34568544 | Inhibitory activity of FDA-approved drugs cetilistat, abiraterone, diiodohydroxyquinoline, bexarotene, remdesivir, and hydroxychloroquine on COVID-19 main protease and human ACE2 receptor: A comparative in silico approach. | 2021 |
1 |
| 6 |
34631362 | Molecular modeling of the interaction of ligands with ACE2-SARS-CoV-2 spike protein complex. | 2021 |
1 |
| 7 |
34746476 | Metabologenomics approach to the discovery of novel compounds from Streptomyces sp. GMR22 as anti-SARS-CoV-2 drugs. | 2021 Nov |
1 |
| 8 |
32607511 | A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19. | 2020 Jun 23 |
1 |
| 9 |
32643603 | Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment. | 2020 Aug 6 |
1 |
| 10 |
32793908 | Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells. | 2020 Sep 2 |
3 |
| 11 |
33245731 | MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 infection. | 2020 Nov 17 |
5 |